cyrilzakka/clinical-trials huggingface dataset:
The Age-related Changes of Energy Metabolism in Physically Fit Adult Males

The influence of age and physical fitness level on the level of energy metabolism and antioxidant capacity in adult males.

Over four hundred healthy, adult males of different age categories and physical fitness levels were included in the study. There is much research convincing that in athletes of various sports disciplines the level of energy metabolism, oxidative stress, and amino acid profiles during years of training undergoes sports adaptation. The study aimed to evaluate how age and physical fitness level affects the level of purine metabolites and metabolites of nicotinamide adenine dinucleotide, the level of antioxidant capacity, and amino acid profiles. Investigators hypothesized that there will be an age-related decline in most of the physiological indices, but significant differences will appear regarding the level of an individual's sports adaptation.

Eligibility Criteria:
Inclusion Criteria:

1. healthy
2. non-smoking
3. physically fit, including top-level athletes

Exclusion Criteria:

1. no reported history of a cardiopulmonary or renal diseases, and other chronic diseases
2. no major orthopedic injury or illness resulting in an inability to run
3. no medications that could affect cardiopulmonary functions
4. normal resting electrocardiogram
5. body mass index (BMI) below 30.0 kg·m-2
6. normal erythrocyte count and Hb content
7. no pathological states known of significantly elevated adenylate pool and concentration of ATP, e.g. sickle cell disease, diabetes, leukemia, sepsis, tuberculosis, meningococcal infection, or renal insufficiency
Intrauterine Device Versus Uterine Artery Embolization for Adenomyosis

The primary purpose of this study is to compare the therapeutic efficacy of intrauterine device and uterine artery embolization for uterine adenomyosis.

Screening

* History, Physical examination
* Laboratory test (Hemoglobin) / MRI
* Pictorial blood loss assessment chart
* Symptom/Quality of life score

Intervention

* Intrauterine device or uterine artery embolization
* Adverse event montoring

Follow-up visit #1 (1 month)

* Vital signs
* blood test (Hemoglobin) / Ultrasound
* Adverse event monitoring

Follow-up visit #2 (3 month)

• MRI only for embolization patients

Follow-up visit #3 (6 months)

* Blood test (Hemoglobin) / Ultrasound
* Pictorial blood loss assessment chart
* Symptom/Quality of life score

Follow-up visit #4 (12months)

* Blood test (Hemoglobin) / Ultrasound
* Pictorial blood loss assessment chart
* Symptom/Quality of life score

Eligibility Criteria:
Inclusion Criteria:

1. Women with symptomatic fibroids (age: 19 - 48 years old) 2. Hemglobin \< 12g/dL, 3. Symptoms of adenomysis (Menorrhagia, Dysmenorrhea)

Exclusion Criteria:

1. Gynecologic malignancy 2. Ongoing infection or inflammation 3. Coagulopathy (platelet \< 50,000 or INR \> 1.5) 4. Concomitant endometriosis 5. Pregnancy
Ketamine Infusion vs Dexmedetomidine Infusion in Obese Patients Undergoing Bariatric Surgery

The surgeries that involve treatment of morbid obesity, i.e. bypass procedure and sleeve gastrectomy, are collectively covered under the term 'bariatric surgery'. The frequency of bariatric surgery has been increasing worldwide for patients with medically complicated obesity who have difficulty losing weight by other methods

The growth of bariatric surgery is accompanied with development of anesthetic techniques to maintain patient safety and improve outcome. Treatment with narcotics in obese patients has dual effect. Increased use of narcotics are associated with multiple complications including Postoperative Nausea and Vomiting (PONV) , respiratory depression and elevated risk of Obstructive Sleep Apnea (OSA) complications . On the other hand, the reduction in opioid use may result in acute post-operative pain that may limit post-surgery rehabilitation. Therefore, we need to minimize opioid use and employ some other drugs which, besides having analgesia, has an opioid-sparing effect also.

Ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has analgesic properties in sub-anesthetic doses. When used in low dose (0.3 to 0.5 mg/kg) by ideal body weight, it is an analgesic, anti-hyperalgesic, and prevents development of opioid tolerance.

Dexmedetomidine is selective α2-Adrenoceptor agonist that has been used as an adjuvant to anesthetic agents in perioperative period for several adventitious profile as well as tolerated side effects . While dexmedetomidine is emerging as a beneficial adjunct to the analgesic regimen in the perioperative period, its utilization is not routinely widespread .


Eligibility Criteria:
Inclusion Criteria:

* BMI \> 35 kg/m2
* ASA physical status II \& III (according to BMI)
* Undergoing laparoscopic bariatric surgery

Exclusion Criteria:

* Patients refusal
* ASA physical status: IV (according to BMI)
* History of hypersensitivity to dexmedetomidine and/or ketamine
* History of substance abuse (Benzodiazepines) or Chronic opioid use
* Psychiatric or Seizure disorder
* uncontrolled hypertension or heart block
* uncontrolled diabetes
* Surgical Complication
HIV Self-testing in Implementation PrEP Study

This is a sub-study of an ongoing PrEP study ( HIV PrEP for men who have sex with men - MSM - and transgender women - TGW: a demonstrative project in Brazil, Peru and Mexico - ImPrEP). MSM/TGW enrolled to ImPrEP Study at the selected sites, who agree to participate in this HIV Self Test (HIVST) sub-study, will be 1:1 randomized at the third study visit either to receive 5 HIVST+voucher (intervention arm) or 5 vouchers alone (control arm) to secondarily distribute into their MSM/TGW network. All vouchers are numbered invitations for priority access to individualized HIV risk assessment and combination prevention services, including PrEP, at the ImPrEP sites. Study population comprises ImPrEP participants and their referred peers. Sample size is going to be determined at an interim analysis performed when each city has enrolled 70 participants. Trial participants will be at maximum 876 (438 intervention and 438 in the control arm) MSM and TGW included in the ImPrEP Study who received PrEP for at least 6 months in the sites from Rio de Janeiro and Lima. The study is designed as a multicenter, open, adaptative, randomized trial. The main study outcome is the voucher redemption proportion by arm.


Eligibility Criteria:
Inclusion Criteria:

* individuals who were included in the ImPrEP Study
* performed at least 3 study visits,
* accepted to participate in this sub study,
* provide informed consent form

Exclusion Criteria:

* Individuals included into ImPrEP as a result of HIVST secondary distribution
A Study to Identify Markers in Blood and Tissue of HPV Clearance

This is a research study looking at gene characteristics in blood and Pap smear samples in hopes of identifying markers that will predict if the HPV infection is present or not.

Because infection with high-risk human papillomavirus is a necessary cause of cervical cancer, HPV testing has many potential uses in cervical cancer screening. Unfortunately, like cytology, it suffers from a lack of specificity when used for population-based screening. Given that HPV testing detects more cases of CIN3+ than cytology and that it would probably be more practical in developing regions, finding a biomarker that would increase specificity has been the goal for much research on HPV and cervical cancer. The goal of this study is to explore potential predictors of viral clearance, specifically RNA levels of candidate genes in cervical swabs and host genetic polymorphisms, in the context of genotype-specific infection data.

Eligibility Criteria:
Inclusion Criteria:

* HPV positive

Exclusion Criteria:

* Negative for HPV
A Study on Different Treatments for Knee Osteoarthritis Caused by Damaged Roots of the Medial Meniscus.

Medial meniscus posterior root tears (MMPRT) account for 20% or more of all meniscus tears, but the diagnosis and treatment of this condition continues to plague the general population due to the complexity of the diagnosis and uncertainty of the treatment. Early as well as timely diagnosis and treatment is one of the effective ways to avoid accelerated knee degeneration. Based on this study, our team is going to conduct a clinical study on posterior medial meniscus tear, combining Magnetic Resonance Imaging(MRI) to dynamically assess the changes of meniscus and articular cartilage surface after the injury, and selecting a specific patient group to carry out different therapeutic interventions, which mainly include conservative treatment, partial meniscectomy, and meniscal repair, in order to clarify the effects of different treatment modalities on the articular cartilage after the posterior meniscus tear, and to help to delay the degeneration of knee joints. This is to clarify the effects of different treatment modalities on the articular cartilage after posterior medial meniscus tears and to provide appropriate advice for delaying the progression of osteoarthritis of the knee.


Eligibility Criteria:
Inclusion Criteria:

1. Clinical diagnosis of posterior root tear of the medial meniscus;
2. Patients with K-L classification ≤ grade II;
3. The age range of 50-65 years old;
4. International Cartilage Repair Society (ICRS) Modified Magnetic Resonance Imaging Grading System ≤ Grade 2;
5. International Cartilage Repair Society (ICRS) arthroscopic grading system ≤ grade 2;
6. Knee joint mobility ≥90°;
7. Inversion deformity ≤10°;
8. Must be able to complete follow-up MRI within 2 years after knee meniscus surgery;
9. Must be able to complete clinical data;

Exclusion Criteria:

1. Can not participate in this study;
2. Patients with concomitant meniscal injuries elsewhere;
3. knee joint infection disease;
4. Osteoporosis disease;
5. Patients with previous history of knee surgery;
6. Knee joint instability disease;
7. Severe KOA disease;
8. Can not cooperate with MRI detection;
9. Cannot tolerate the surgery;
10. Those who cannot tolerate the arthroscopic knee surgery;
11. Neuromuscular system pathology disease;
Melatonin Supplementation to Improve Sleep in Patients With Heart Failure

The purpose of this study is to determine whether melatonin can improve sleep, quality of life and markers of heart failure in patients with heart failure.

Heart failure affects nearly 5 million individuals in the United States and constitutes a prime risk factor for morbidity and mortality. Beta-blockers are a class of drugs that form a critical part of the best treatment of heart failure, and thereby decrease the risk for these serious problems. Beta-blockers also lower the levels of melatonin, a hormone that has a sleep-promoting effect. Most patients with heart failure take beta-blockers and have poor sleep, which may be related to the beta-blockers' effect on melatonin levels. This study will evaluate the effectiveness of treatment with melatonin supplements in improving sleep in individuals with heart failure who are taking beta-blockers. In addition, the study will examine whether the melatonin supplements aid in improving quality of life and measures of heart failure.

Participants in this double-blind study will be randomly assigned to receive either melatonin supplements or placebo for the duration of the study.

The study will mainly take place at home, where participants will complete sleep diaries, measure blood pressure and wear a wrist watch that measures movement for 5-6 weeks. During that time there will be three visits to the hospital where plasma and urine samples will be collected and questionnaires will be completed.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed with heart failure NYHA Class 2 or 3
* Currently being treated with beta-blocker

Exclusion Criteria:

* Diagnosed with obstructive sleep apnea
* Using Fluvoxamine, Warfarin, Nifedipine, or Calcium Channel Blockers
Study Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique

Intrauterine devices (IUDs) are contraceptive methods of long-acting (from 3 to 10 years depending on the model) and among the most effective. However, there are many obstacles to the use of IUDs including pain felt by patients during installation. Several medical means were studied without evidence of their efficacy in pain related to IUD insertion. In order to remove this brake, it's important to find another way to act against this pain. The direct technique is one of the techniques described by health professionals. It seems trusted by its users as a more reliable technique but also less painful for patients. However, there is no study available on its evaluation. The aim of this study is to investigate the interest of the direct technique in reducing the pain experienced by patients during installation.


Eligibility Criteria:
Inclusion Criteria:

* Any major patient and consultant for IUD insertion : hormonal or copper
* Signing of the information and consent form by the patient or, if under supervision by parents or guardian.
* Patient affiliated with or entitled to a social security scheme
* No contraindication for IUD insertion

Exclusion Criteria:

* Patient consultant for IUD insertion to side arms
* Contraindications for installation.
* Legal incapacity or limited legal capacity. Medical or psychological conditions not allowing the subject to understand the study and sign the consent
* Refusal to sign the consent.
Immediate Effects of Kinesio Tape on Median Nerve's Mechanosensitivity

The purpose of this study is to verify the immediate effects of Kinesio Tape on median nerve's mechanosensitivity, measured by the upper limb neurodynamic test 1 (ULNT1) in healthy participants.

After completing the socio-demographic and clinical questionnaire, the participants will be randomly assigned into two designated groups, the Intervention Group (IG; n = 30) (Kinesio tape throughout the median nerve course) and the Control Group (CG; n = 30) (remained at rest for 5 minutes), using the software www.graphpad.com/quickcals.

Eligibility Criteria:
Inclusion Criteria:

* Healthy university students of both genders with normal mobility of the joints of the upper quadrant of the body

Exclusion Criteria:

* Deformities in the upper quadrant region of the body;

  * Complaints in this region in the last 6 months;
  * Surgical procedures or musculoskeletal, cardiac, renal, metabolic, neurological and or oncological pathologies of the upper quadrant that may disturb nerve function;
  * Not present any mechanosensitive response to ULNT1;
  * Pregnant women;
  * Ingestion of non-steroidal anti-inflammatory drugs or consumption of any type of narcotic drugs and participants who have drunk alcohol in the last 12 hours.
Evaluation of Diet and Exercise in Prostate Cancer Patients

Canadian Real Life Evaluation of the Effect of Diet and Exercise in Prostate Cancer Patients Managed with Lupron.

This is a study utilizing a prospective cohort design. Patients with Prostrate cancer (PCa) who are prescribed Lupron will be entered into the study cohort and will be followed for a maximum of 18 months with recommended assessments at 3, 6, 12 and 18 months after Day 1. Treatment of the patients and follow up will be according to the physicians' judgment, regional regulations and the product monograph.

Eligibility Criteria:
Inclusion Criteria:

i. Adult ≥ 18 years old

ii. Has provided written informed consent allowing the use of their data for the study and providing permission for contact by the study personnel.

iii. Diagnosed with PCa.

iv. Prescribed Lupron as part of his treatment by his treating physician.

Exclusion Criteria:

i. Patient cannot or will not sign informed consent.

ii. Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of PCa.

iii. More than 6 months of therapy if currently on continuous Luteinizing hormone-releasing hormone (LHRH) treatment.

iv. If at study enrollment the intent is to only prescribe 1 dose of Lupron (leuprolide acetate)
Randomized Prospective Trial: Single Port Laparoscopic Vertical Sleeve Gastrectomy Versus Conventional Five Port Laparoscopic Vertical Sleeve Gastrectomy Surgery

Vertical Sleeve Gastrectomy has been shown to significantly reduce weight and has been approved as a treatment of morbid obesity. The standard laparoscopic operation requires five small incisions for the introduction of instruments and the band into the patient's abdomen. The investigators have developed a technique for performing this operation through a single incision at the belly button. This study compares this method to the conventional 5-incision approach.


Eligibility Criteria:
Inclusion Criteria:

* BMI \>40
* ASA I or II

Exclusion Criteria:

* Comorbid cardiac, pulmonary, renal, hepatic disease
* Bleeding disorder
* Previous gastric/esophageal surgery
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

This randomized, open-label study was designed to evaluate and compare the safety and efficacy of atezolizumab with gemcitabine + cisplatin or carboplatin in PD-L1 selected participants with chemotherapy-naive, Stage IV squamous NSCLC. The study was closed due to low patient enrollment and the Sponsor's decision to include patients with squamous NSCLC into the GO29431 study, NCT02409342. Therefore the planned objectives of this study are no longer applicable and formal analyses of efficacy or safety have not been performed.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically confirmed Stage IV squamous NSCLC
* Tumor programmed death-ligand 1 (PD-L1) expression, as determined by immunohistochemistry (IHC) assay of archival tumor tissue or tissue obtained at screening
* No prior treatment for Stage IV squamous NSCLC
* Measurable disease as defined by RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
* Adequate hematologic and end-organ function

Exclusion Criteria:

* Active or untreated central nervous system (CNS) metastases
* Untreated or inadequately treated spinal cord compression
* Leptomeningeal disease
* Uncontrolled pleural effusion, pericardial effusion, or ascites
* Uncontrolled tumor-related pain
* Uncontrolled hypercalcemia
* Any other malignancies within 5 years except those with negligible risk of metastasis or death
* Pregnant or lactating women
* Known hypersensitivity to any component of atezolizumab formulation or other study medication
* History of autoimmune disease except controlled, treated hypothyroidism or type I diabetes
* Prior allogeneic bone marrow or solid organ transplantation
* Positive human immunodeficiency virus (HIV) test
* Active hepatitis B or C
* Active tuberculosis
* Significant cardiovascular disease
* Severe infection or major surgery within 4 weeks prior to randomization
* Use of any approved anti-cancer therapy within 3 weeks prior to treatment
* Use of an investigational agent or participation in another clinical trial within 4 weeks prior to randomization
* Exposure to oral or IV antibiotics within 2 weeks or live attenuated vaccines within 4 weeks prior to randomization
* Prior treatment with cluster of differentiation (CD) 137 agonists or immune checkpoint blockade therapies, anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies
* Treatment with immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks prior to randomization
Oral Health Assessment of Children in CP Class

Few oral exams are performed on 6-year-olds (key age for carious disease). This project aims to increase the number of oral check-ups for 6-year-olds in fragile areas (REP/REP+ areas).


Eligibility Criteria:
Inclusion criteria:

* Be a first-grade student enrolled in a school in a zone REP/REP+
* Have a parental permission
* Good understanding of the French language

Exclusion criteria:

- lack of parental permission
The Effect of Extra Virgin Olive Oil in People With Multiple Sclerosis

This is an open label feasibility trial to examine the effect of a complementary treatment with High Phenolic Extra Virgin Olive Oil (HPEVOO) on the cognitive and mental health of people with Multiple Sclerosis (MS), while receiving their standard medical treatment.


Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of MS
* Must be between 18 to 65 years of age
* Both males and females are eligible for participation
* Must have at least five years of education
* Must be fluent in Greek language

Exclusion Criteria:

* Other neurological, psychiatric or chronic condition
* Enrollment in other trials/drug studies
* Experiencing side effects from previous treatments
* Inadequate visual and auditory acuity
Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia

In a prospective randomized clinical trial involving adult patients undergoing elective surgery under general anesthesia, the investigators will enroll 216 patients, and evaluate 3 doses of prophylactic dexmedetomidine as a means to reduce postoperative shivering and quality of emergence from anesthesia versus placebo.

Patients undergoing surgery under general anesthesia may experience several complications during the postoperative period. Shivering has been reported to occur in up to 65% of patients recovering from general anesthesia, and has been shown to cause detrimental effects to the patient. Previous studies have shown that dexmedetomidine 1µg/kg at the end of surgery significantly reduces the incidence of postoperative shivering and improves quality of emergence from anesthesia. However, this beneficial effect of dexmedetomidine is at the expense of prolonged time to extubation and awakening. The aim of this study is to find the optimal dose of dexmedetomidine that would be beneficial without delaying recovery from general anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* 18-80 year-old
* ASA class I, II, and III
* patients undergoing elective surgery under general anesthesia with an estimated time of 1-3 h

Exclusion Criteria:

* duration of surgery less than 1h or more than 3 h
* allergy to dexmedetomidine
* vasoactive antidepressant or analgesics
* obesity (BMI\>30)
* fever
* pregnancy